Results 61 to 70 of about 1,287 (121)

Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes. [PDF]

Hypertens Res
Katsuya T, Nakatsu F, Eguchi S, Nakamura Y, Matsukawa M, Iekushi K, Hiramitsu S.   +6 more
europepmc   +1 more source

Memory impairment with symmetrical hippocampal lesions following acute glufosinate-ammonium intoxication. [PDF]

BMJ Case Rep
Antunes D, Pereira DJ, Brás P, Jesus-Ribeiro J.   +3 more
europepmc   +1 more source

Effectiveness of Sacubitril/Valsartan in Reducing Hospitalizations in Older Belgian Adults with Heart Failure and Reduced Ejection Fraction: An Age-Stratified Study. [PDF]

Drugs Aging
Maury E, Van der Linden L, Bogaerts K, Belmans A, Jansen M.   +4 more
europepmc   +1 more source

Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update. [PDF]

Alzheimers Res Ther
Garnier-Crussard A.
europepmc   +1 more source

The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies. [PDF]

Int J Mol Sci
Salerno ENM, Fumarulo I, Mendicino C, Vaccarella M, Garramone B, Gallo F, Volzone G, Cammuso A, Della Candelora V, Scaldaferri F, Lopetuso LR, Gasbarrini A, Burzotta F, Aspromonte N.   +13 more
europepmc   +1 more source

Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease. [PDF]

J Clin Hypertens (Greenwich)
Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T.   +5 more
europepmc   +1 more source

Predicting cardiac and renal responses to sacubitril/valsartan with a mathematical model of heart failure with preserved ejection fraction. [PDF]

Am J Physiol Heart Circ Physiol
Clemmer JS, Hall ME, Mallette JH, Pruett WA.   +3 more
europepmc   +1 more source

Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy. [PDF]

Circulation
McGurk KA, Bilgehan N, Ware JS.
europepmc   +1 more source

Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice. [PDF]

J Clin Hypertens (Greenwich)
Horio T, Iwashima Y, Yoshiyama M, Fukuda D, Rai T, Fujimoto K.   +5 more
europepmc   +1 more source

The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. [PDF]

Heart Fail Rev
Mecinaj A, Vinje-Jakobsen V, Ngo DTM, Sverdlov AL, Myhre PL.   +4 more
europepmc   +1 more source